Vaccinia as a vector for gene delivery (Q35790868)

10 August 2017

1 reference

title

Vaccinia as a vector for gene delivery (English)

1 reference

10 August 2017

Z Sheng Guo

1

1 reference

PubMed ID

15174972

10 August 2017

David L Bartlett

series ordinal

2

1 reference

PubMed ID

15174972

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

6

1 reference

10 August 2017

901-917

1 reference

Vaccinia virus: a tool for research and vaccine development

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Poxvirus vectors: cytoplasmic expression of transferred genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The complete DNA sequence of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Use of chemokine receptors by poxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Intracellular and extracellular vaccinia virions enter cells by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Membrane topology of the vaccinia virus A17L envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The A17L gene product of vaccinia virus is exposed on the surface of IMV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Antibody neutralization of the extracellular enveloped form of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Transcription factor YY1 is a vaccinia virus late promoter activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Poxviruses as expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

A dominant selectable marker for the construction of recombinant poxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus: a selectable eukaryotic cloning and expression vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Duration of antiviral immunity after smallpox vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The formation and function of extracellular enveloped vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Modulation of chemokines by poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Applications of pox virus vectors to vaccination: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The emerging fields of suicide gene therapy and virotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Selectively replicating viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Cidofovir in the treatment of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Deaths in vaccine trials trigger French inquiry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: construction and characterization of a tetracycline-inducible recombinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Development of a DNA-MVA/HIVA vaccine for Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

The prime-boost strategy: exciting prospects for improved vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Improved protection conferred by vaccination with a recombinant vaccinia virus that incorporates a foreign antigen into the extracellular enveloped virion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.901

21 January 2018

Identifiers

DOI

10.1517/14712598.4.6.901

1 reference

10 August 2017

1 reference

PubMed ID

15174972